Pathophysiology of acne;Pathophysiologie der akne

JDDG - Journal of the German Society of Dermatology

Volumn 5, Issue 4, 2007, Pages 316-323

  Degitz, Klaus ^a,b   Placzek, Marianne ^a   Borelli, Claudia ^a   Plewig, Gerd ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Dermatologische Gemeinschaftspraxis Schatz Barth and Degitz   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANABOLIC AGENT; ANDROGEN; CHLORAL HYDRATE; CORTICOTROPIN; CYANOCOBALAMIN; CYPROTERONE ACETATE; DACTINOMYCIN; DISULFIRAM; GLUCOCORTICOID; ISONIAZID; LITHIUM; METHOXSALEN; NANDROLONE DERIVATIVE; PHENYTOIN; PYRIDOXINE; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TETRACYCLINE DERIVATIVE;

ACNE; ADENOMA; ADRENAL CORTEX; AGE DISTRIBUTION; CARCINOMA; CHLORACNE; COMEDO; CONGENITAL ADRENAL HYPERPLASIA; CUSHING SYNDROME; DARIER DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HYPERANDROGENISM; KARYOTYPE; MENSTRUAL CYCLE; MICROBIAL COLONIZATION; OVARY FOLLICLE CELL; OVARY POLYCYSTIC DISEASE; OVARY TUMOR; REVIEW; SEBACEOUS GLAND; SEBORRHEA; SKIN EPITHELIUM;

EID: 33947501293     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2007.06274.x     Document Type: Review

References (15)

1. Plewig G, Kligman AM. Acne and rosacea, 3rd edn., Springer, Berlin, 2000.
2. Gollnick HP, Cunliffe WJ. Management of acne. A report from a global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49: S1-S38.
3. Gollnick HP. Leitlinien "Akne und ihre Subtypen". Hautarzt 2002; 53: 322-327.
4. Herane MI, Ando I. Acne in infancy and acne genetics. Dermatol 2003; 206: 24-28.
5. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J Invest Dermatol 2003; 121: 20-27.
6. Zouboulis CC, Xia L, Akamatsu H, Seltmann H, Hornemann S, Rühl R, Chen W, Nau H, Orfanos CE. The human sebocyte culture model provides insights into development and management of seborrhea and acne. Dermatol 1998; 196: 21-31.
7. Leyden J, Bergfeld W, Drake L, Dunlap F, Goldman MP, Gottlieb AB, Heffernan MP, Hickman JG, Hordinsky M, Jarrett M, Kang S, Lucky A, Peck G, Phillips T, Rapaport M, Roberts J, Savin R, Sawaya ME, Shalita A, Shavin J, Shaw JC, Stein L, Stewart D, Strauss J, Swinehart J, Swinyer L, Thiboutot D, Washenik K, Weinstein G, Whiting D, Pappas F, Sanchez M, Terranella L, Waldstreicher J. A systemic type I 5 alpha-reductase inhibitor is ineffective in the treatment of acne vulgaris. J Am Acad Dermatol 2004; 50: 443-447.
8. Placzek M, Arnold B, Schmidt H, Gaube S, Keller E, Plewig G, Degitz K. Elevated 17-hydroxyprogesterone serum values in male patients with acne. J Am Acad Dermatol 2005; 53: 955-958.
9. Degitz K, Placzek M, Arnold B, Plewig G. Endokrinologische Aspekte bei Akne. In: Plewig G, Degitz K, (Hrsg): Fortschritte der praktischen Dermatologie und Venerologie, Vol. 17. Berlin: Springer, 2001: 172-179.
10. Zouboulis CC, Böhm M. Neuroendocrine regulation of sebocytes - a pathogenetic link between stress and acne. Exp Dermatol 2004; 13 (Suppl. 4): 31-35.
11. Guy R, Green MR, Kealey T. Modeling acne in vitro. J Invest Dermatol 1996; 106: 176-182.
12. Kim J, Ochoa MT, Krutzik SR, Takeuchi O, Uematsu S, Legaspi AJ, Brightbill HD, Holland D, Cunliffe WJ, Akira S, Sieling PA, Godowski PJ, Modlin RL. Activation of toll-like receptor 2 in acne triggers inflammatory cytokine responses. J Immunol 2002; 169: 1535-1541.
13. Zouboulis CC, Nestoris S, Adler YD, Orth M, Orfanos CE, Picardo M, Camera E, Cunliffe WJ. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor. Arch Dermatol 2003; 139: 668-670.
14. Grabmeier B, Landthaler M, Hohenleutner S. Menstruationszyklus und Haut. JDDG 2005; 3: 52-64.
15. Orth DN, Kovacs WJ. The adrenal cortex. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, (eds): Williams textbook of endocrinology. Philadelphia: W.B. Saunders, 1998: 517-664.